TP53 and breast cancer: Conversely, MDM2, a negative regulator of p53, was negatively correlated with immune cell infiltration, supporting its role in immune evasion and poor prognosis through the suppression of CD4+ and CD8+ T-cell activity across multiple malignancies, including breast cancer [49].